Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dapoxetine Delay: J&J’s Premature Ejaculation Drug “Not Approvable” At FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Alza says it will continue the global development program and address FDA’s questions.
Advertisement

Related Content

Reviving The Premature Ejaculation Field; Sciele/Plethora Start Final Phase III
Reviving The Premature Ejaculation Field; Sciele/Plethora Start Final Phase III
J&J Pipeline On Track; Tapentadol Filing Expected This Week
J&J Pipeline On Track; Tapentadol Filing Expected This Week
J&J Plans Dapoxetine Meeting With FDA, Awaits Agency Actions
J&J Plans Dapoxetine Meeting With FDA, Awaits Agency Actions
Dapoxetine Early 2006 Launch Expectations Premature, J&J Says
Dapoxetine Early 2006 Launch Expectations Premature, J&J Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS061166

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel